The neuroinflammatory triumvirate: NF-κB, NLRP3, and mTOR in spinal cord injury.

IF 5.3 2区 医学 Q2 IMMUNOLOGY
Ali Darabniya
{"title":"The neuroinflammatory triumvirate: NF-κB, NLRP3, and mTOR in spinal cord injury.","authors":"Ali Darabniya","doi":"10.1007/s10787-025-01952-2","DOIUrl":null,"url":null,"abstract":"<p><p>After spinal cord injury (SCI), there is a finely choreographed neuroinflammatory response that can profoundly influence secondary injury, neuronal apoptosis, the formation of a glial scar, and long-term functional recovery outcomes. The key multifaceted roles within this neuroinflammatory process are mediated through the NF-κB, NLRP3 inflammasome, and mTOR signaling pathways, which function as interconnected networks controlling cytokine production, the reactivity of astrocytes and microglia, autophagy, and apoptosis. Dysregulation of these pathways leads to increased neuroinflammation and chronic neurological deficits.Emerging preclinical studies demonstrate how targeting single pathways with monotherapy shows modest success; however, with the co-targeting of NF-κB, NLRP3, and mTOR, neuroprotection is achieved through a reduction in inflammatory cascades, stimulation of autophagy, reduction of glial scarring, and ultimately, functional recovery was achieved. New therapeutic strategies, including selective pharmacological inhibitors, multi-gene-based biotechnology, and next-generation biomaterial-assisted therapeutic delivery systems, are emerging and are of interest towards maximizing outcomes while minimizing systemic toxicity. This review details the mechanisms and interactions of NF-κB, NLRP3, and mTOR in SCI, providing a comprehensive overview of upstream regulators, downstream effectors, and feedback loops to regulate cross-talk; emerging multi-target strategies with a view to translational viability and challenges; and the future focus on precision neuroinflammatory modulation. A sophisticated grasp of these interconnected signaling frameworks provides a conceptual framework for next-generation neuroprotective treatments, with the potential to greatly attenuate secondary injury, induce better neural repair, and improve long-term neurological outcomes. Integrative, pathway-targeted approaches have the potential to revolutionize the management of SCI and more effectively expedite the real-world translation of mechanistic-based approaches into clinical interventions.</p>","PeriodicalId":13551,"journal":{"name":"Inflammopharmacology","volume":" ","pages":""},"PeriodicalIF":5.3000,"publicationDate":"2025-09-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Inflammopharmacology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s10787-025-01952-2","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"IMMUNOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

After spinal cord injury (SCI), there is a finely choreographed neuroinflammatory response that can profoundly influence secondary injury, neuronal apoptosis, the formation of a glial scar, and long-term functional recovery outcomes. The key multifaceted roles within this neuroinflammatory process are mediated through the NF-κB, NLRP3 inflammasome, and mTOR signaling pathways, which function as interconnected networks controlling cytokine production, the reactivity of astrocytes and microglia, autophagy, and apoptosis. Dysregulation of these pathways leads to increased neuroinflammation and chronic neurological deficits.Emerging preclinical studies demonstrate how targeting single pathways with monotherapy shows modest success; however, with the co-targeting of NF-κB, NLRP3, and mTOR, neuroprotection is achieved through a reduction in inflammatory cascades, stimulation of autophagy, reduction of glial scarring, and ultimately, functional recovery was achieved. New therapeutic strategies, including selective pharmacological inhibitors, multi-gene-based biotechnology, and next-generation biomaterial-assisted therapeutic delivery systems, are emerging and are of interest towards maximizing outcomes while minimizing systemic toxicity. This review details the mechanisms and interactions of NF-κB, NLRP3, and mTOR in SCI, providing a comprehensive overview of upstream regulators, downstream effectors, and feedback loops to regulate cross-talk; emerging multi-target strategies with a view to translational viability and challenges; and the future focus on precision neuroinflammatory modulation. A sophisticated grasp of these interconnected signaling frameworks provides a conceptual framework for next-generation neuroprotective treatments, with the potential to greatly attenuate secondary injury, induce better neural repair, and improve long-term neurological outcomes. Integrative, pathway-targeted approaches have the potential to revolutionize the management of SCI and more effectively expedite the real-world translation of mechanistic-based approaches into clinical interventions.

神经炎性三巨头:NF-κB、NLRP3和mTOR在脊髓损伤中的作用。
脊髓损伤(SCI)后,有一个精心设计的神经炎症反应,可以深刻影响继发性损伤、神经元凋亡、胶质瘢痕的形成和长期功能恢复结果。在这一神经炎症过程中,关键的多方面作用是通过NF-κB、NLRP3炎性体和mTOR信号通路介导的,这些信号通路作为相互连接的网络,控制细胞因子的产生、星形胶质细胞和小胶质细胞的反应性、自噬和凋亡。这些通路失调导致神经炎症增加和慢性神经功能缺损。新兴的临床前研究表明,单一疗法靶向单一途径取得了一定的成功;然而,通过NF-κB、NLRP3和mTOR的共同靶向,通过减少炎症级联、刺激自噬、减少胶质瘢痕,最终实现功能恢复,从而实现神经保护。新的治疗策略,包括选择性药物抑制剂、基于多基因的生物技术和下一代生物材料辅助治疗递送系统,正在出现,并对最大化结果和最小化全身毒性感兴趣。本文详细介绍了NF-κB、NLRP3和mTOR在脊髓损伤中的作用机制和相互作用,全面概述了调控串扰的上游调控因子、下游效应因子和反馈回路;基于翻译可行性和挑战的新兴多目标策略未来的重点是精确的神经炎症调节。对这些相互关联的信号框架的复杂掌握为下一代神经保护治疗提供了一个概念框架,具有极大地减轻继发性损伤、诱导更好的神经修复和改善长期神经预后的潜力。综合的、靶向通路的方法有可能彻底改变脊髓损伤的管理,并更有效地加快现实世界中基于机械的方法向临床干预的转化。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Inflammopharmacology
Inflammopharmacology IMMUNOLOGYTOXICOLOGY-TOXICOLOGY
CiteScore
8.00
自引率
3.40%
发文量
200
期刊介绍: Inflammopharmacology is the official publication of the Gastrointestinal Section of the International Union of Basic and Clinical Pharmacology (IUPHAR) and the Hungarian Experimental and Clinical Pharmacology Society (HECPS). Inflammopharmacology publishes papers on all aspects of inflammation and its pharmacological control emphasizing comparisons of (a) different inflammatory states, and (b) the actions, therapeutic efficacy and safety of drugs employed in the treatment of inflammatory conditions. The comparative aspects of the types of inflammatory conditions include gastrointestinal disease (e.g. ulcerative colitis, Crohn''s disease), parasitic diseases, toxicological manifestations of the effects of drugs and environmental agents, arthritic conditions, and inflammatory effects of injury or aging on skeletal muscle. The journal has seven main interest areas: -Drug-Disease Interactions - Conditional Pharmacology - i.e. where the condition (disease or stress state) influences the therapeutic response and side (adverse) effects from anti-inflammatory drugs. Mechanisms of drug-disease and drug disease interactions and the role of different stress states -Rheumatology - particular emphasis on methods of measurement of clinical response effects of new agents, adverse effects from anti-rheumatic drugs -Gastroenterology - with particular emphasis on animal and human models, mechanisms of mucosal inflammation and ulceration and effects of novel and established anti-ulcer, anti-inflammatory agents, or antiparasitic agents -Neuro-Inflammation and Pain - model systems, pharmacology of new analgesic agents and mechanisms of neuro-inflammation and pain -Novel drugs, natural products and nutraceuticals - and their effects on inflammatory processes, especially where there are indications of novel modes action compared with conventional drugs e.g. NSAIDs -Muscle-immune interactions during inflammation [...]
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信